Antihypertensive agents in Alzheimer’s disease: beyond vascular protection
暂无分享,去创建一个
[1] Nick C Fox,et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study , 2019, The Lancet Neurology.
[2] Mohammad R. Ostovaneh,et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial , 2019, The Lancet.
[3] Jackson T. Wright,et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. , 2019, JAMA.
[4] B. Lawlor,et al. Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. , 2019, Hypertension.
[5] R. Segurado,et al. Blood Pressure Lowering With Nilvadipine in Patients With Mild‐to‐Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension , 2019, Journal of the American Heart Association.
[6] N. Nalivaeva,et al. Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy , 2019, British journal of pharmacology.
[7] David C. Zhu,et al. Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD Study). , 2019, Contemporary clinical trials.
[8] J. Williamson,et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial , 2019, JAMA.
[9] Eric E. Smith,et al. Vascular dysfunction—The disregarded partner of Alzheimer's disease , 2019, Alzheimer's & Dementia.
[10] P. Kehoe,et al. The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity , 2018, PloS one.
[11] R. Segurado,et al. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial , 2018, PLoS medicine.
[12] R. Apte,et al. Microglial Activation Is Modulated by Captopril: in Vitro and in Vivo Studies , 2018, Front. Cell. Neurosci..
[13] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[14] Shih-Ying Wu,et al. Hypertension Accelerates Alzheimer’s Disease-Related Pathologies in Pigs and 3xTg Mice , 2018, Front. Aging Neurosci..
[15] C. Rowe,et al. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions , 2018, Nature Reviews Neurology.
[16] Berislav V. Zlokovic,et al. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.
[17] P. Kehoe,et al. Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial. , 2017, Journal of Alzheimer's disease : JAD.
[18] P. Bertolucci,et al. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia. , 2017, Current Alzheimer research.
[19] R. Lipton,et al. Association Between Vascular Pathology and Rate of Cognitive Decline Independent of Alzheimer's Disease Pathology , 2017, Journal of the American Geriatrics Society.
[20] R. Bateman,et al. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid‐&bgr; concentrations and clearance in the cynomolgus monkey , 2017, Toxicology and applied pharmacology.
[21] D. Campbell,et al. Long-term neprilysin inhibition — implications for ARNIs , 2017, Nature Reviews Cardiology.
[22] B. Winblad,et al. The worldwide costs of dementia 2015 and comparisons with 2010 , 2017, Alzheimer's & Dementia.
[23] Sudha Seshadri,et al. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association , 2016, Hypertension.
[24] R. Apte,et al. Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies , 2016, PloS one.
[25] D. Werring,et al. Novel imaging techniques in cerebral small vessel diseases and vascular cognitive impairment. , 2016, Biochimica et biophysica acta.
[26] P. Pal,et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects , 2015, British journal of clinical pharmacology.
[27] Gerald W. Zamponi,et al. Targeting voltage-gated calcium channels in neurological and psychiatric diseases , 2015, Nature Reviews Drug Discovery.
[28] S. Love,et al. Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex. , 2016, Journal of Alzheimer's disease : JAD.
[29] A. Cohen-Solal,et al. Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split? , 2015, European heart journal.
[30] T. Psaltopoulou,et al. Vascular risk factors and Alzheimer's disease pathogenesis: are conventional pharmacological approaches protective for cognitive decline progression? , 2015, CNS & neurological disorders drug targets.
[31] E. Dere,et al. Hypertension Accelerates the Progression of Alzheimer-Like Pathology in a Mouse Model of the Disease , 2015, Hypertension.
[32] T. Bayer,et al. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.
[33] J. O'Brien,et al. Vascular risk factors and Alzheimer’s disease , 2014, BMC Medicine.
[34] L. Pantoni,et al. Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review , 2014, BMC Medicine.
[35] F. Crawford,et al. The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation* , 2014, The Journal of Biological Chemistry.
[36] K. Abe,et al. Strong reduction of low-density lipoprotein receptor/apolipoprotein E expressions by telmisartan in cerebral cortex and hippocampus of stroke resistant spontaneously hypertensive rats. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[37] Cheuk Y. Tang,et al. Brain imaging changes associated with risk factors for cardiovascular and cerebrovascular disease in asymptomatic patients. , 2014, JACC. Cardiovascular imaging.
[38] R. Segurado,et al. NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease , 2014, BMJ Open.
[39] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[40] X. Tong,et al. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model , 2014, Neurobiology of Disease.
[41] Kristine Yaffe,et al. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data , 2014, The Lancet Neurology.
[42] J. Laks,et al. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). , 2014, Arquivos de neuro-psiquiatria.
[43] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[44] Shuyu Liu,et al. Differential effects of angiotensin II receptor blockers on Aβ generation , 2014, Neuroscience Letters.
[45] L. Kuller,et al. Arterial stiffness and β-amyloid progression in nondemented elderly adults. , 2014, JAMA neurology.
[46] D. Butterfield,et al. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. , 2014, Biochemical pharmacology.
[47] Pau-Chung Chen,et al. Angiotension receptor blockers reduce the risk of dementia , 2014, Journal of hypertension.
[48] K. Black,et al. Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline. , 2014, The Journal of clinical investigation.
[49] M. Fornage,et al. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.
[50] C. Gong,et al. Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit. , 2014, Journal of Alzheimer's disease : JAD.
[51] M. Ramírez,et al. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice. , 2013, The international journal of neuropsychopharmacology.
[52] C. Ballard,et al. Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease , 2013, Pharmaceuticals.
[53] Qian-Li Xue,et al. Antihypertensive drugs decrease risk of Alzheimer disease , 2013, Neurology.
[54] L. Launer,et al. Antihypertensive medication use and risk of cognitive impairment , 2013, Neurology.
[55] J. Trojanowski,et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. , 2013, Brain : a journal of neurology.
[56] U. Quitterer,et al. ACE Inhibition with Captopril Retards the Development of Signs of Neurodegeneration in an Animal Model of Alzheimer’s Disease , 2013, International journal of molecular sciences.
[57] M. Ramírez,et al. Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration. , 2013, The international journal of neuropsychopharmacology.
[58] M. Woodward,et al. Baseline Cognitive Function, Recurrent Stroke, and Risk of Dementia in Patients With Stroke , 2013, Stroke.
[59] G. Guyatt,et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia , 2013, BMJ Open.
[60] M. O. Bostanci,et al. Blocking of L-type calcium channels protects hippocampal and nigral neurons against iron neurotoxicity The role of L-type calcium channels in iron-induced neurotoxicity , 2013, The International journal of neuroscience.
[61] Sagar H. Barage,et al. Molecular Dynamics Simulation and Molecular Docking Studies of Angiotensin Converting Enzyme with Inhibitor Lisinopril and Amyloid Beta Peptide , 2013, The Protein Journal.
[62] Ian F. Harrison,et al. Prazosin, an α1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease , 2013, Neurobiology of Aging.
[63] Li-sheng Liu,et al. A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists , 2013, Pharmacological Reviews.
[64] Tzeng-Ji Chen,et al. Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population--a nationwide cohort study. , 2013, Circulation journal : official journal of the Japanese Circulation Society.
[65] M. Ramírez,et al. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model , 2013, Neuropharmacology.
[66] F. Khodagholi,et al. L-type calcium channel blockade alleviates molecular and reversal spatial learning and memory alterations induced by entorhinal amyloid pathology in rats , 2013, Behavioural Brain Research.
[67] J. Cummings,et al. A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents , 2013, Dementia and Geriatric Cognitive Disorders.
[68] G. Pasinetti,et al. Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[69] P. Kehoe,et al. Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. , 2013, Journal of Alzheimer's disease : JAD.
[70] F. Di Virgilio,et al. Nimodipine inhibits IL‐1β release stimulated by amyloid β from microglia , 2012, British journal of pharmacology.
[71] K. Irie,et al. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. , 2012, Biological & pharmaceutical bulletin.
[72] Paul Edison,et al. Drug repositioning for Alzheimer's disease , 2012, Nature Reviews Drug Discovery.
[73] Donglin Zhu,et al. Central angiotensin II‐induced Alzheimer‐like tau phosphorylation in normal rat brains , 2012, FEBS letters.
[74] M. Mogi,et al. Peroxisome Proliferator-Activated Receptor-&ggr; Activation With Angiotensin II Type 1 Receptor Blockade Is Pivotal for the Prevention of Blood-Brain Barrier Impairment and Cognitive Decline in Type 2 Diabetic Mice , 2012, Hypertension.
[75] H. Hanyu,et al. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease , 2012, Geriatrics & gerontology international.
[76] H. Brodaty,et al. Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention , 2012, Translational Psychiatry.
[77] K. Gupta,et al. Reserpine modulates neurotransmitter release to extend lifespan and alleviate age-dependent Aβ proteotoxicity in Caenorhabditis elegans , 2012, Experimental Gerontology.
[78] V. Mathura,et al. Apolipoprotein E genotype‐specific short‐term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients—an open‐label trial , 2011, International journal of geriatric psychiatry.
[79] Sterling C. Johnson,et al. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. , 2012, Journal of Alzheimer's disease : JAD.
[80] B. Zlokovic. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.
[81] D. Werring,et al. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[82] V. Mathura,et al. Demonstration of safety in Alzheimer's patients for intervention with an anti‐hypertensive drug Nilvadipine: results from a 6‐week open label study , 2011, International journal of geriatric psychiatry.
[83] S. Black,et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.
[84] D. Paris,et al. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. , 2011, European journal of pharmacology.
[85] C. Volmar,et al. Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier , 2011, Molecular medicine.
[86] R. Mayeux,et al. Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.
[87] H. Kobori,et al. Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. , 2011, American journal of hypertension.
[88] S. Yusuf,et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.
[89] L. Ruilope,et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study , 2010, The Lancet.
[90] T. Ogihara,et al. Angiotensin Receptor Blocker Prevented &bgr;-Amyloid–Induced Cognitive Impairment Associated With Recovery of Neurovascular Coupling , 2009, Hypertension.
[91] M. Mogi,et al. Cognitive Deficit in Amyloid-&bgr;–Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-&ggr; Activation , 2009, Hypertension.
[92] B. Winblad,et al. Low Diastolic Pressure and Risk of Dementia in Very Old People: A Longitudinal Study , 2009, Dementia and Geriatric Cognitive Disorders.
[93] Jane B Shofer,et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[94] O. Hanon,et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. , 2009, American journal of hypertension.
[95] J. Williamson,et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. , 2009, Archives of internal medicine.
[96] J. Subramaniam,et al. Reserpine ameliorates Aβ toxicity in the Alzheimer’s disease model in Caenorhabditis elegans , 2009, Experimental Gerontology.
[97] V. Haroutunian,et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons , 2009, Neurology.
[98] A. Hofman,et al. Duration of antihypertensive drug use and risk of dementia , 2009, Neurology.
[99] Guojun Bu,et al. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.
[100] W. Banks,et al. Angiotensin II Modulates BBB Permeability via Activation of the AT1 Receptor in Brain Endothelial Cells , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[101] D. Teplow,et al. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. , 2009, Journal of Alzheimer's disease : JAD.
[102] Qi-dong Yang,et al. Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease. , 2008, Chinese medical journal.
[103] Jian-Mei Li,et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. , 2008, Biochemical and biophysical research communications.
[104] C. Bulpitt,et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.
[105] I. McKeith,et al. Candesartan and cognitive decline in older patients with hypertension , 2008, Neurology.
[106] L. Kenton,et al. Combined but not Individual Administration of β-Adrenergic and Serotonergic Antagonists Impairs Water Maze Acquisition in the Rat , 2008, Neuropsychopharmacology.
[107] Dietmar Rudolf Thal,et al. Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease , 2008, Acta Neuropathologica.
[108] Hiroshi Matsuda,et al. Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. , 2008, Clinical nuclear medicine.
[109] Wei Zhao,et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. , 2007, The Journal of clinical investigation.
[110] M. Hüll,et al. Drug Insight: effects mediated by peroxisome proliferator-activated receptor-γ in CNS disorders , 2007, Nature Clinical Practice Neurology.
[111] W. Geldenhuys,et al. Voltage-gated Calcium Channels Provide an Alternate Route for Iron Uptake in Neuronal Cell Cultures , 2007, Neurochemical Research.
[112] D. Selkoe,et al. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease , 2007, Neurobiology of Disease.
[113] K. Mishima,et al. Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats. , 2007, Biological & pharmaceutical bulletin.
[114] V. Ozacmak,et al. AT1 Receptor Blocker Candesartan-induced Attenuation of Brain Injury of Rats Subjected to Chronic Cerebral Hypoperfusion , 2007, Neurochemical Research.
[115] K. Jellinger. The enigma of mixed dementia , 2007, Alzheimer's & Dementia.
[116] M. Hüll,et al. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. , 2007, Nature clinical practice. Neurology.
[117] G. Livingston,et al. Relationship of vascular risk to the progression of Alzheimer disease , 2006, Neurology.
[118] O. Hanon,et al. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints , 2006, Journal of hypertension.
[119] Hilkka Soininen,et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study , 2006, The Lancet Neurology.
[120] Y. Pang,et al. Bis(7)‐tacrine attenuates β amyloid‐induced neuronal apoptosis by regulating L‐type calcium channels , 2006, Journal of neurochemistry.
[121] H. Kobori,et al. New Generation Calcium Channel Blockers in Hypertensive Treatment. , 2006, Current hypertension reviews.
[122] P. Zandi,et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. , 2006, Archives of neurology.
[123] Lenore J Launer,et al. Reducing the Risk of Dementia: Efficacy of Long-Term Treatment of Hypertension , 2006, Stroke.
[124] A. Burgo,et al. Nimodipine selectively stimulates β-amyloid 1–42 secretion by a mechanism independent of calcium influx blockage , 2006, Neurobiology of Aging.
[125] A. Zanchetti,et al. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) – A review , 2006, Blood pressure.
[126] D. Selkoe,et al. Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor* , 2005, Journal of Biological Chemistry.
[127] M. Woodward,et al. Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke: The PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy , 2005, Circulation.
[128] A. Hofman,et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE) , 2005, Alzheimer's & Dementia.
[129] Alessandro Padovani,et al. Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy , 2005, International journal of geriatric psychiatry.
[130] P. Stang,et al. Hypertension and the Rate of Cognitive Decline in Patients With Dementia of the Alzheimer Type , 2004, Alzheimer disease and associated disorders.
[131] B. Winblad,et al. Decline in Blood Pressure Over Time and Risk of Dementia: A Longitudinal Study From the Kungsholmen Project , 2004, Stroke.
[132] Philip Scheltens,et al. Midlife Blood Pressure and the Risk of Hippocampal Atrophy: The Honolulu Asia Aging Study , 2004, Hypertension.
[133] P. Ghisdal,et al. Intraneuronal amyloid‐β1‐42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death , 2004, Journal of neurochemistry.
[134] Fiona Crawford,et al. Nilvadipine antagonizes both Aβ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice , 2004, Brain Research.
[135] T. Shea,et al. Okadaic acid mediates tau phosphorylation via sustained activation of the L-voltage-sensitive calcium channel. , 2003, Brain research. Molecular brain research.
[136] B. Winblad,et al. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD , 2003, Neurology.
[137] C. Herron,et al. A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. , 2003, Journal of neurophysiology.
[138] Neil Chapman,et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.
[139] D. Cain,et al. Combined β-Adrenergic and Cholinergic Antagonism Produces Behavioral and Cognitive Impairments in the Water Maze: Implications for Alzheimer Disease and Pharmacotherapy with β-Adrenergic Antagonists , 2003, Neuropsychopharmacology.
[140] D. Cain,et al. Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists. , 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[141] Jan A Staessen,et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.
[142] T. Sakaeda,et al. Effects of endothelin B receptor agonists on amyloid β protein (25–35)-induced neuronal cell death , 2002, Brain Research.
[143] David A. Calhoun,et al. Drugs targeting the renin–angiotensin–aldosterone system , 2002, Nature Reviews Drug Discovery.
[144] J. Birks,et al. Nimodipine for primary degenerative, mixed and vascular dementia. , 2002, The Cochrane database of systematic reviews.
[145] T. Saido,et al. Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.
[146] A. Hofman,et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.
[147] T. Shea,et al. Amyloid-beta promotes calcium influx and neurodegeneration via stimulation of L voltage-sensitive calcium channels rather than NMDA channels in cultured neurons. , 2001, Journal of Alzheimer's disease : JAD.
[148] K. Hall,et al. The Association Between Vascular Risk Factor‐Mediating Medications and Cognition and Dementia Diagnosis in a Community‐Based Sample of African‐Americans , 2000, Journal of the American Geriatrics Society.
[149] W. Markesbery,et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS☆ , 2000, Neurobiology of Aging.
[150] C. Dufouil,et al. Cognitive decline in individuals with high blood pressure , 1999, Neurology.
[151] J. Tuomilehto,et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.
[152] C. Cotman,et al. Rapid Communication: Ca2+ Channel Blockers Attenuate β‐Amyloid Peptide Toxicity to Cortical Neurons in Culture , 1994 .
[153] C. Cotman,et al. Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. , 1994, Journal of neurochemistry.